Clinical Advisor11h
Tau-Targeting Antisense Therapy for Alzheimer Disease Gets Fast Track Status
BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...
Managed Healthcare Executive9h
Caregiver Burden and Value Assessments in Duchenne Muscular Dystrophy
Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...
Labiotech.eu18h
Beyond amyloid: The search for the next big thing in Alzheimer’s treatment
Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.
Advanced Cervical Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...